Aptevo Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, except share amounts)
| Additional · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders' | ||||||||
| Shares · Amount · Capital · Deficit · Equity | ||||||||
| Balance at December 31, 2023 | 33 | $61 | $235,607 | $(223,447) | 12,221 | |||
| Common stock issued upon vesting of restricted stock units and exercised stock options | — | — | (1) | — | (1) | |||
| Payment in lieu of fractional shares (1) | — | — | (3) | — | (3) | |||
| Issuance of common stock net of issuance cost (2) | 1,731 | 22 | 9,542 | — | 9,564 | |||
| Warrant inducement, net of issuance cost | 1 | 5,562 | 5,563 | |||||
| Warrant modification - incremental fair value | 2,287 | — | 472 | — | 472 | |||
| Stock-based compensation | — | — | 1,069 | — | 1,069 | |||
| Net loss for the period | — | — | — | (24,130) | (24,130) | |||
| Balance at December 31, 2024 | 4,051 | $84 | $252,248 | $(247,577) | $4,755 | |||
| Payment in lieu of fractional shares (1) | (39) | — | — | — | — | |||
| Issuance of common stock net of issuance cost (3) | 993,818 | 30 | 38,467 | — | 38,497 | |||
| Stock-based compensation | — | — | 96 | — | 96 | |||
| Dividend attributable to down round feature of warrants | — | — | 1,571 | (1,571) | — | |||
| Net loss for the period | — | — | — | (25,967) | (25,967) | |||
| Balance at December 31, 2025 | 997,830 | $114 | $292,382 | $(275,115) | $17,381 | |||
(1) Payments were made in lieu of fractional shares in connection with the reverse stock splits occurred in 2024 and 2025.
(2)Includes gross proceeds of $11.5 million less issuance costs of $1.9 million, which includes $0.5 million warrant modification incremental fair value.
(3) Includes gross proceeds of $39.4 million less issuance costs of $0.9 million.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.